Pharmafile Logo
Pharmafocus logo
Advanced Search
ipsen-logo-big

Ipsen acquires Blueprint drug and moves further into ultra-rare disease

October 17, 2019
Research and Development

Ipsen has announced that through its subsidiary Clementia Pharmaceuticals, it has entered into an exclusive, worldwide license agreement for the …

News

Lilly’s pegilodecakin combo falls at Phase 3 in pancreatic cancer

October 17, 2019
Research and Development Cancer, Eli Lilly, FOLFOX, Pancreatic cancer, pegilodecakin, pharma

In disappointing news, Eli Lilly has revealed that pegilodecakin, in combination with the chemotherapy regimen FOLFOX (Folinic acid, Fluorouracil and …

News

AstraZeneca receives FDA Priority Review for breast cancer drug

October 17, 2019
Research and Development

AstraZeneca have announced that the US FDA has granted Priority Review for its experimental breast cancer treatment trastuzumab. The Prescription …

News
andrew_dickinson

Gilead appoints Andrew Dickinson as CFO

October 16, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Gilead Sciences have announced that Andrew Dickinson has been appointed as Chief Financial Officer (CFO) effective 1 November. Dickinson currently …

Appointment
_dsc6281_1

Medical cannabis: Riding the wave

October 16, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kanabo research, medical cannabis, pharma

Following on from our previous piece from Mewburn Ellis on the history of social attitudes towards cannabis, Israel-based Kanabo Research …

Feature
shutterstock_273326141

Alexion to acquire Achillion Pharma for $930 million

October 16, 2019
Research and Development, Sales and Marketing Alexion, achillion, merger, pharma

Alexion has revealed it has signed a definitive agreement to acquire Achillion Pharmaceuticals in a deal valued at $930 million, …

News
eisa0008_web

China approves Eisai’s Fycompa for partial onset epileptic seizures

October 16, 2019
Research and Development, Sales and Marketing China, Eisai, Fycompa, epilepsy, pharma

Tokyo-headquartered firm Eisai has announced that its antiepileptic drug (AED) Fycompa (perampanel) has received approval from China’s National Medical Products …

News

FDA approves first and only transdermal patch for schizophrenia

October 16, 2019
Research and Development, Sales and Marketing FDA, Noven Pharma, Secuado, US, pharma, schizophrenia

Hisamitsu Pharmaceutical subsidiary Noven Pharmaceuticals has revealed the FDA approval of Secuado (asenapine) in adult schizophrenia patients, making it the …

News
mitigating-burdens-of-tbi

Tranexamic acid to prevent brain bleeds could save thousands of lives

October 15, 2019
Research and Development

A large controlled clinical trial has linked the early use of tranexamic acid to a small fall in the risk …

News
takeda_world

Takeda sheds 30 products in emerging markets in $200m deal

October 15, 2019
Research and Development

Takeda has sold selected prescription and over the counter products to Acino in the Near East, Middle East and Africa …

News
london-2393098_960_720

New UK Medicines Bill could improve access to new dementia treatments

October 15, 2019
Manufacturing and Production

The Government has announced new legislation aimed at providing faster access to medicines, including those treating dementia and Alzheimer’s.The Medicines …

News

Lilly’s Reyvow becomes first FDA-approved 5-HT1F receptor agonist for acute migraine

October 15, 2019
Manufacturing and Production, Sales and Marketing Eli Lilly, FDA, Reyvow, US, migraine, pharma

Eli Lilly has announced that the FDA has given the green light to Reyvow (lasmiditan) in the acute treatment of …

News
180802_parkinsons_uk

New £1.2m trial for Parkinson’s patients testing cannabidiol

October 15, 2019
Manufacturing and Production

A new clinical trial at King’s College London will investigate the use of cannabidiol (CBD) – a compound found in …

News
janssen_latest_logo_on_sign_closer

FDA approves Janssen’s Xarelto for blood clot prevention

October 15, 2019
Manufacturing and Production, Sales and Marketing FDA, Janssen, US, Xarelto, pharma, thromboembolism

Janssen’s Xarelto (rivaroxaban) has secured FDA approval for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalised acutely …

News
17806842-15615029782758005_origin

Reata reports top-line data for omaveloxolone in Freidreich’s ataxia

October 15, 2019
Manufacturing and Production

Reata has reported that Part 2 of its mid-stage MOXIe trial of its Nrf2 activator omaveloxolone met its primary endpoint. …

News
_dsc6538

Medical cannabis: On to greener pastures?

October 14, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing medical cannabis, medicinal cannabis, pharma

In the first of three articles on the topic, Callum McGuinn, Associate and European Patent Attorney at Mewburn Ellis, explores …

Feature

Pfizer reveals strong Phase 3 data for abrocitinib in atopic dermatitis

October 14, 2019
Research and Development, Sales and Marketing Pfizer, abrocitinib, atopic dermatitis, pharma

Pfizer confirmed over the weekend that its oral Janus kinase 1 (JAK1) inhibitor abrocitinib met all of its co-primary and …

News
index_ph001

Daiichi Sankyo show low CV events and bleeding in NVAF patients on Lixiana

October 14, 2019
Sales and Marketing

Daiichi Sankyo have announced one-year follow-up results from an analysis of 12,574 European non-valvular atrial fibrillation (NVAF) patients treated with …

News
shionogi

Shionogi reports positive results for cefiderocol in pneumonia

October 14, 2019
Sales and Marketing

Shionogi has reported positive data from a trial of its investigational antibiotic cefiderocol which is already under regulatory review in …

News
roche__tree

Roche’s Phase 3 Pemphix trial smashes primary endpoint for pemphigus vulgaris

October 14, 2019
Research and Development, Sales and Marketing MabThera, Rituxan, Roche, pharma

Roche has revealed new Phase 3 data demonstrating that its MabThera/Rituxan (rituximab) therapy Pemphix met its primary endpoint in the …

News
The Gateway to Local Adoption Series

Latest content

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026